(“Sareum” or “the Company”)

Sareum to Participate in the Edison Open House: Global Healthcare 2021

Cambridge, UK, 26 January 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that its Chief Executive Officer, Dr Tim Mitchell, is participating today in a virtual interview at the Edison Open House: Global Healthcare 2021 event, taking place online between 26 and 28 January 2021.

Dr Mitchell’s session will take place between 14:30 and 15:00 GMT on Tuesday 26 January.

The following link can be used to register:

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO



01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman



020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse



020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible


020 7638 9571

About EOP:GH 2021

The Edison Open House: Global Healthcare 2021 (EOP:GH 2021) is a virtual conference with a mission – to open up access to the booming universe of healthcare stocks to the widest possible audience.

The event will explore the case for investing in a carefully curated selection of microcap stocks – as well as demystify the global megatrends behind the boom in healthcare investment which, in the third quarter of last year alone, saw a record £1 billion raised in the UK.

Thousands of institutions, family offices, wealth managers and individual investors – as well journalists, entrepreneurs and investment banks – will be hosted across the three days.

EOP:GH 2021 was created by Edison and is brought to you in partnership with the Spark Live, the streaming platform from London Stock Exchange Group (LSEG), and law firm Taylor Wessing.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at